NCT04085471

Brief Summary

The purpose of the study is to determine whether plasma levels of the collagen triple helix repeat containing (CTHRC1) protein can serve as a blood-based biomarker for diagnosis of rheumatoid arthritis (RA) ,and furthermore its correlation with disease activity.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
90

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Oct 2019

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 9, 2019

Completed
2 days until next milestone

First Posted

Study publicly available on registry

September 11, 2019

Completed
20 days until next milestone

Study Start

First participant enrolled

October 1, 2019

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2020

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2020

Completed
Last Updated

September 18, 2019

Status Verified

September 1, 2019

Enrollment Period

1 year

First QC Date

September 9, 2019

Last Update Submit

September 16, 2019

Conditions

Rheumatoid Arthritis

Outcome Measures

Primary Outcomes (1)

  • CTHRC1 Apromising biomarker in rheumatoid arthritis diagnosis

    measurement of levels of CTHRC1 in rheumatoid arthritis patients

    one year

Interventions

CTHRC1 biomarker level in rheumatoid arthritisDIAGNOSTIC_TEST

measurment of levels of CTHRC1 in patients diagnosed as RA

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

measurement of CTHRC1in RA patints

You may qualify if:

  • Patients diagnosed as RA.
  • Patients ( \>18)who are age and sex matched with the controls

You may not qualify if:

  • Other Rheumatologic diseases. .Patients with malignancy . .Patients with hepatic disease .

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Myatt GL, Ecobichon DJ, Greenhalgh R. Fenitrooxon and S-methyl fenitrothion: acute toxicity and hydrolysis in mammals. Environ Res. 1975 Dec;10(3):407-14. doi: 10.1016/0013-9351(75)90036-5. No abstract available.

    PMID: 2462BACKGROUND

MeSH Terms

Conditions

Arthritis, Rheumatoid

Condition Hierarchy (Ancestors)

ArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic DiseasesConnective Tissue DiseasesSkin and Connective Tissue DiseasesAutoimmune DiseasesImmune System Diseases

Central Study Contacts

Lobna Amer Araby, Master

CONTACT

01019313530lobnaamer20@gmail.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal investigator

Study Record Dates

First Submitted

September 9, 2019

First Posted

September 11, 2019

Study Start

October 1, 2019

Primary Completion

October 1, 2020

Study Completion

December 1, 2020

Last Updated

September 18, 2019

Record last verified: 2019-09